Compared to PBS group, vaccination with LN-TCV group showed higher levels of DCs recruitment (indicated by the number of CD11c+ cells) and maturation (indicated by the percentages of CD11c+MHC I+ and CD80+CD86+ cells), owing to the improved tumor antigen uptake mediated by NPs (Supplementary Fig. 7) and the adjuvant effect of endogenous HSPs released from LN-TCV (Supplementary Figs. 8, 9). The gene discussed is CD80; the disease is neoplasm.